CITATION REPORT List of articles citing

Vascular disorders of the liver

DOI: 10.1002/hep.22772 Hepatology, 2009, 49, 1729-64.

Source: https://exaly.com/paper-pdf/46061034/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF		Citations
724	Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. 2010 , 44, 448-51		315
723	Thrombose porte et mBentEique en dehors de la cirrhose. 2010 , 4, 27-33		2
722	[Acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult and complicated with an abdominal compartment syndrome]. 2010 , 34, e3-5		6
721	Hereditary haemorrhagic telangiectasia. 2010 , 34, 475-6		1
720	The preferable treatment for cirrhotic portal vein thrombosis: anticoagulation or transjugular intrahepatic portosystemic shunt?. <i>Hepatology</i> , 2010 , 51, 713-4	1.2	14
719	Systematic review: portal vein thrombosis in cirrhosis. 2010 , 31, 366-74		207
718	Ascites in patients with noncirrhotic nonmalignant extrahepatic portal vein thrombosis. 2010 , 32, 529-34		19
717	The epidemiology and clinical features of portal vein thrombosis: a multicentre study. 2010 , 32, 1154-62		110
716	Haemostasis and thrombosis in liver disease. 2010 , 148, 507-21		81
7 ¹ 5	Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. 2010 , 16, 143-55		179
714	Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?. 2010 , 11, 1479-87		12
713	Sinusoidal obstruction syndrome. 2010 , 14, 651-68		68
712	[Hepatic lesions induced by systemic chemotherapy for digestive cancer]. 2010 , 30, 421-5		4
711	Portal vein thrombosis, revisited. 2010 , 42, 163-70		97
710	Bile salts and cholestasis. 2010 , 42, 409-18		115
709	Management of varices and variceal hemorrhage in cirrhosis. 2010 , 362, 823-32		700
708	The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. 2011 , 117, 3968-73		36

(2011-2011)

707	Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. 2011 , 31, 485-93	43
706	Vascular Diseases of the Liver. 2011 , 909-923	
7°5	Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. 2011 , 43, 503-14	43
704	Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis. 2011 , 9, 936-46; quiz e123	17
703	Cardiovascular diseases and the liver. 2011 , 15, 1-20	42
702	A rare cause of portal vein thrombosis in a previously healthy young man with acute hepatitis. 2011 , 51, 152-4	5
701	Bleeding in patients with Budd-Chiari syndrome. 2011 , 54, 56-63	45
700	Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. 2011 , 54, 78-88	238
699	Stage of portal vein thrombosis. 2011 , 54, 1080-2; author reply 1082-3	15
698	Thrombophilic dimension of Budd chiari syndrome and portal venous thrombosisa concise review. 2011 , 127, 505-12	33
697	Vascular Disorders of the Liver. 2011 , 443-454	1
696	Hepatic venous outflow obstruction complicating Churg-Strauss syndrome in a 5-year-old child. 2011 , 52, 217-8	6
695	Acoustic radiation force impulse elastography and contrast-enhanced sonography of sinusoidal obstructive syndrome (Veno-occlusive Disease): preliminary results. 2011 , 30, 1593-8	26
694	Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. 2011 , 33, 1087-103	55
693	Hypercoagulability in cirrhosis: causes and consequences. 2011 , 9, 1713-23	182
692	Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. 2011 , 56, 2166-78	89
691	[Acute hepatic vascular complications]. 2011 , 52, 795-6, 798-800, 802-3	1
690	[Diffuse and vascular hepatic diseases]. 2011 , 51, 704-13	1

689	A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings. 2011 , 29, 579-83	8
688	High incidence of hepatitis B infection-associated cirrhosis and hepatocellular carcinoma in the Southeast Asian patients with portal vein thrombosis. 2011 , 11, 66	21
687	Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. 2011 , 17, 565-72	46
686	Prediction, prevention and management of postresection liver failure. 2011 , 98, 1188-200	137
685	Symptomatic liver involvement in neonatal hereditary hemorrhagic telangiectasia. 2011 , 127, e1615-20	19
684	A large portal vein: a rare finding of recent portal vein thrombosis. 2011 , 5, 33-9	4
683	Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. 2011 , 10, 687-96	44
682	Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. 2012 , 120, 4921-8	243
681	Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. 2012 , 265, 124-32	191
680	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. 2012 , 3, 253-65	32
679	Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review. 2012 , 2012, 672986	32
678	Maladies vasculaires du foie. 2012 , 7, 1-7	
677	Aszites, Pfortaderthrombose und hepatische Enzephalopathie bei Leberzirrhose: Aktuelle Therapieempfehlungen. 2012 , 28, 297-303	1
676	Enfermedades hepticas de causa cardiovascular. 2012 , 11, 601-607	
675	Cirrosis hep E ica. 2012 , 11, 625-633	4
674	Protocolo diagn¤tico y tratamiento del s¤drome de Budd-Chiari primario. 2012 , 11, 723-727	
673	Protocolo diagnEtico y tratamiento de la trombosis portal no cirrEica. 2012 , 11, 728-732	
672	Management of hepatic vascular diseases. 2012 , 56 Suppl 1, S25-38	146

(2012-2012)

671	CT features of non-malignant portal vein thrombosis: a pictorial review. 2012 , 36, 561-8	21
670	The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. 2012 , 34, 388-96	17
669	Acute portal vein thrombosis complicating in vitro fertilization. 2012, 98, 1470-3	5
668	A bad streak. 2012 , 142, 432-3, 677	
667	Pregnancy in women with portal vein thrombosis: results of a multicentric European study on maternal and fetal management and outcome. 2012 , 57, 1214-9	33
666	Enfermedades vasculares hepEicas. 2012 , 16, 1-8	
665	Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. 2012 , 10, 776-83	336
664	Malattie vascolari del fegato. 2012 , 14, 1-7	
663	Acute toxische hepatitis. 2012, 28, 53-61	
662	Anticoagulation for cirrhotic portal vein thrombosis: bold, brave, and possibly beneficial. 2012 , 10, 784-5	8
662	Anticoagulation for cirrhotic portal vein thrombosis: bold, brave, and possibly beneficial. 2012 , 10, 784-5 [Thrombosis of abdominal veins]. 2012 , 33 Suppl 1, S25-9	8 0
661		
661	[Thrombosis of abdominal veins]. 2012 , 33 Suppl 1, S25-9	0
661 660	[Thrombosis of abdominal veins]. 2012 , 33 Suppl 1, S25-9 Anticoagulation in cirrhosis. 2012 , 32, 878-9 Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic	6
661 660 659	[Thrombosis of abdominal veins]. 2012, 33 Suppl 1, S25-9 Anticoagulation in cirrhosis. 2012, 32, 878-9 Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. 2012, 5, 291-302	o 6 37
661 660 659	[Thrombosis of abdominal veins]. 2012, 33 Suppl 1, S25-9 Anticoagulation in cirrhosis. 2012, 32, 878-9 Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. 2012, 5, 291-302 Portal vein thrombosis, cirrhosis, and liver transplantation. 2012, 57, 203-12	o 6 37 153
661 660 659 658	[Thrombosis of abdominal veins]. 2012, 33 Suppl 1, S25-9 Anticoagulation in cirrhosis. 2012, 32, 878-9 Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. 2012, 5, 291-302 Portal vein thrombosis, cirrhosis, and liver transplantation. 2012, 57, 203-12 Abdominal thromboses of splanchnic, renal and ovarian veins. 2012, 25, 253-64	o 6 37 153 25

653	Vascular Diseases of the Gastrointestinal Tract. 2012 , 928-937		1
652	Vascular disorders. 2012 , 601-643		16
651	Portal Hypertension and Bleeding Esophageal Varices. 2012 , 296-326		6
650	Budd-Chiari Syndrome and Sinusoidal Obstruction Syndrome (Hepatic Venoocclusive Disease). 2012 , 793-811		
649	Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. 2012 , 18, 819-27		25
648	Budd-Chiari syndrome and venoocclusive disease. 2012 , 1188-1222.e6		
647	Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients. 2012 , 57, 1072-82		136
646	Transjugular intrahepatic portosystemic shunt in the treatment of portal vein thrombosis: a critical review of literature. 2012 , 6, 576-90		37
645	Veno-occlusive disease following high dose melphalan. 2012 , 28, 62-3		2
644	Cavernous vessels around a patent portal trunk in the liver hilum. 2012 , 37, 422-30		4
643	Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. 2012 , 13, 33-9		84
642	Portal vein thrombosis in 33 dogs: 1998-2011. 2012 , 26, 230-7		64
641	Budd-Chiari syndrome in children and outcome after liver transplant. 2012 , 16, E338-41		8
640	Budd-Chiari syndrome revisited: 38 years@xperience with surgical portal decompression. 2012 , 16, 286-300; discussion 300		42
639	Compendium of national guidelines for imaging of the pediatric patient. 2012, 42, 82-94		5
638	AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. <i>Hepatology</i> , 2013 , 58, 2142-52	11.2	43
637	Vascular Diseases of the Liver. 2013 , 1135-1168		
636	Role of anticoagulant therapy in liver disease. 2013 , 7, 369-76		5

(2013-2013)

635	Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. 2013 , 58, 1776-80	103
634	Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. 2013 , 28, 432-42	56
633	Living donor liver transplantation for Budd-Chiari syndrome with hepatic inferior vena cava obstruction after open pericardial procedures. 2013 , 43, 1180-4	8
632	Exudative ascites as presenting manifestation of latent essential thrombocytemia. 2013, 1, 4-7	
631	Liver in haematological disorders. 2013 , 27, 513-30	12
630	Splanchnic vein thrombosis in myeloproliferative neoplasms. 2013 , 162, 730-47	45
629	Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. 2013 , 20, 1462-9	17
628	Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. 2013 , 11, 452-9	69
627	Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. 2013 , 38, 1025-37	44
626	Portal vein thrombosis: should anticoagulation be used?. 2013 , 15, 306	21
625	Secondary Budd-Chiari syndrome complicating calcified right atrial thrombosis related to ventriculoatrial shunt. 2013 , 102, 165-8	1
624	Prevalence of paroxysmal nocturnal hemoglobinuria in Chinese patients with Budd-Chiari syndrome or portal vein thrombosis. 2013 , 28, 148-52	33
623	Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of	
	anticoagulation and long-term follow-up. 2013 , 24, 1808-16	28
622		34
	anticoagulation and long-term follow-up. 2013 , 24, 1808-16 Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to	
622	anticoagulation and long-term follow-up. 2013 , 24, 1808-16 Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. 2013 , 19, S88-90 BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal	34
622	anticoagulation and long-term follow-up. 2013 , 24, 1808-16 Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. 2013 , 19, S88-90 BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. 2013 , 163, 444-57	34

617	Assessing portal hypertension in liver diseases. 2013 , 7, 141-55		165
616	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). 2013 , 125, 200-19		36
615	Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia. <i>Hepatology</i> , 2013 , 58, 442-5	1.2	7
614	Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. 2013 , 3,		5
613	Right atrium tumor thrombus. 2013, 106, 679-80		2
612	Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. 2013 , 266, 657-67		96
611	Management of portal hypertension in children with portal vein thrombosis. 2013, 57, 419-25		16
610	Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study. 2013 , 28, 1061-7		54
609	Drug safety evaluation of defibrotide. 2013 , 12, 123-36		58
608	Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. 2013 , 109, 878-84		68
607	Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review. 2013 , 25, 830-41		45
606	Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. 2013 , 110, 697-705		68
605	Familial Budd-Chiari Syndrome in China: A Systematic Review of the Literature. 2013, 2013, 763508		2
604	Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. 2013 , 12, 952-958		142
603	Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection. 2013 , 53, 151-5		9
602	Two Cases of Hepatic Sinusoidal Dilatation Mimicking Hepatic Metastases. 2014 , 64, 239		
601	Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. 2014 , 20, 384-91		65
600	Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only therapeutic purposes?. 2014 , 2014, 895839		5

599	Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features. 2014 , 15, 218-25	55
598	Transarterial embolization of a hepatic arteriovenous malformation in an infant using Onyx: a case report and review of the differential diagnosis imaging findings. 2014 , 8, 33-42	4
597	Acute cytomegalovirus infection as a cause of venous thromboembolism. 2014 , 6, e2014041	6
596	From portal to splanchnic venous thrombosis: What surgeons should bear in mind. 2014 , 6, 549-58	23
595	An update on management of Budd-Chiari syndrome. 2014 , 13, 323-326	27
594	Massive Hemorrhage during Percutaneous Transhepatic Portal Vein Thrombolysis. 2014 , 31, 272-5	
593	An overview of current treatment methods for Buddlihiari syndrome. 2014 , 2, 147-157	1
592	Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. <i>Hepatology</i> ,	122
591	Noncirrhotic nontumoral portal vein thrombosis. 2014 , 3, 118-121	12
590	Budd-Chiari syndrome. 2014 , 3, 133-136	2
590 589	Budd-Chiari syndrome. 2014 , 3, 133-136 Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. 2014 , 39, 864-72	2 71
	Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in	
589	Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. 2014 , 39, 864-72 Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications	71
589 588	Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. 2014 , 39, 864-72 Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. 2014 , 34, 1164-75	71 56
589 588 587	Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. 2014, 39, 864-72 Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. 2014, 34, 1164-75 Treatment of acute portal vein thrombosis by nontraditional anticoagulation. <i>Hepatology</i> , 2014, 60, 425-61.2	71 56 60
589 588 587 586	Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. 2014, 39, 864-72 Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. 2014, 34, 1164-75 Treatment of acute portal vein thrombosis by nontraditional anticoagulation. <i>Hepatology</i> , 2014, 60, 425-61.2 Etiology and Complications of Portal Vein Thrombosis. 2014, 30, 375-80	71 56 60 25
589 588 587 586 585	Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd-Chiari syndrome. 2014, 39, 864-72 Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. 2014, 34, 1164-75 Treatment of acute portal vein thrombosis by nontraditional anticoagulation. <i>Hepatology</i> , 2014, 60, 425-61.2 Etiology and Complications of Portal Vein Thrombosis. 2014, 30, 375-80 Nonsurgical Therapeutic Options in Portal Vein Thrombosis. 2014, 30, 388-92	71 56 60 25 6

581	Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension in noncirrhotic patients with portal cavernoma. 2014 , 2014, 659726	15
580	Selection of treatment modalities for Budd-Chiari Syndrome in China: a preliminary survey of published literature. 2014 , 20, 10628-36	26
579	Cholestasis in the Hospitalized Patient. 2014 , 201-228	
578	Endovascular treatment of acute portal vein thrombosis using ultrasound-accelerated catheter-directed thrombolysis. 2014 , 48, 460-5	7
577	Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis of observational studies. 2014 , 44, E480-98	22
576	JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients. 2014 , 29, 208-14	29
575	Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. 2014 , 12, 1801-12.e7	65
574	Cirrhosis development probably arises from chronic micro-vascular ischemia. 2014 , 82, 244	15
573	[Portal vein thrombosis associated with an acute cytomegalovirus infection]. 2014 , 39, 224-30	5
572	Primary Budd-Chiari syndrome in a 3-year-old boy with homozygous factor V Leiden G1691A mutation. 2014 , 173, 393-5	2
571	Budd-chiari syndrome management: Timing of treatment is an open issue. <i>Hepatology</i> , 2014 , 59, 1213 11.2	19
57°	Small hepatic veins Budd-Chiari syndrome. 2014 , 37, 536-9	9
569	Portal vein thrombosis in cirrhosis. 2014 , 4, 320-31	32
568	Inherited risk factors for venous thromboembolism. 2014 , 11, 140-56	84
567	Renal blood flow before and after portosystemic shunt in children with portal hypertension. 2014 , 30, 295-9	1
566	Non-cirrhotic portal hypertensionconcept, diagnosis and clinical management. 2014 , 38, 564-9	17
565	Combined surgical and interventional therapy of acute portal vein thrombosis without cirrhosis: a new effective hybrid approach for recanalization of the portal venous system. 2014 , 218, e79-86	11
564	Diagnosis of thrombophilia/prothrombotic conditions in patients with liver disease. 2014 , 3, 126-128	3

563	Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). 2014 , 4, 332-46		162
562	Gastrointestinal causes of abdominal pain. 2014 , 41, 465-89		4
561	Inherited thrombophilia and the risk of portal vein thrombosis: progress toward individualized anticoagulation in cirrhosis?. 2014 , 12, 1813-4		1
560	Splanchnic and Extrasplanchnic Thrombosis in Cirrhosis: Prophylaxis vs Treatment. 2014 , 13, 224-234		2
559	Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. 2014 , 28, 92-101		47
558	Management of portal vein thrombosis in liver cirrhosis. 2014 , 11, 435-46		172
557	Imaging in clinical decision-making for portal vein thrombosis. 2014 , 11, 308-16		53
556	How I treat splanchnic vein thrombosis. 2014, 124, 3685-91		53
555	Intestinal Infarction Caused by Thrombophlebitis of the Portomesenteric Veins as a Complication of Acute Gangrenous Appendicitis After Appendectomy: A Case Report. 2015 , 94, e1033		4
554	Vascular patterning sets the stage for macro and micro hepatic architecture. 2015 , 244, 497-506		10
553	Letter: portal vein obstructionwhich subset of patients could benefit the most?. 2015 , 41, 909		1
552	Acute Portal Vein Thrombosis: Aetiopathogenesis, Diagnosis and Management. 2015 , 135-150		
551	The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome. <i>Hepatology</i> , 2015 , 62, 956-63	11.2	37
550	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. 2015 , 45, 656-62		36
549	Fibrinolysis status in the Budd-Chiari syndrome in China. 2015 , 26, 721-6		2
548	Reply: To PMID 19399912. <i>Hepatology</i> , 2015 , 62, 657	11.2	1
547	Budd-Chiari syndrome complicating essential thrombocythemia in an adolescent: favorable outcome of TIPS procedure. 2015 , 26, 691-4		2
546	Management of Budd-Chiari syndrome in children: same debated issues as in adults. 2015 , 27, 107-8		7

545	Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. 2015 , 35, 2042-9		29
544	Tusanqi-Related Sinusoidal Obstruction Syndrome in China: A Systematic Review of the Literatures. 2015 , 94, e942		40
543	Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. 2015 , 27, 914-9		65
542	Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis. 2015 , 7, 2774-80		76
541	Imbalance of pro- vs. anti-coagulation factors in Chinese patients with Budd-Chiari syndrome and non-cirrhotic portal vein thrombosis. 2015 , 10, e0119909		2
540	Portal vein thrombosis in cirrhosis: Controversies and latest developments. 2015 , 21, 6769-84		58
539	Imaging Diagnosis of Splanchnic Venous Thrombosis. 2015 , 2015, 101029		21
538	Portal vein thrombosis: What is new?. 2015 , 14, 20-27		43
537	Thrombotic risk factors in Chinese nonmalignant and noncirrhotic patients with portal vein thrombosis: an observational study with a systematic review of the literature. 2015 , 27, 77-83		10
536	Budd-Chiari syndrome. 2015 , 3, 489-500		56
535	Safety of Ascitic Paracentesis in Patients with Budd-Chiari Syndrome on Oral Anticoagulation and Elevated International Normalized Ratio. 2015 , 5, 310-3		2
534	Risk factors of recurrence among 471 Chinese patients with Budd-Chiari syndrome. 2015 , 39, 620-6		11
533	Portal vein thrombosis. 2015 , 5, 22-40		90
532	Review article: portal vein obstructionepidemiology, pathogenesis, natural history, prognosis and treatment. 2015 , 41, 276-92		47
531	Difference in Budd-Chiari syndrome between the West and China. <i>Hepatology</i> , 2015 , 62, 656	11.2	14
530	Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis. 2015 , 13, 585-93		58
529	Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. 2015 , 26, 23-9		100
528	Managing unusual presentations of venous thromboembolism. 2015 , 39, 304-10		2

527	Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis. 2015 , 40, 54-60	26
526	Portal Vein Thrombosis in Patients with Cirrhosis Etiology, Diagnosis, and Management. 2015 , 14, 1-8	
525	Optimal Management of Portal Vein Thrombosis in Patients with Liver Cirrhosis: a Review. 2015 , 14, 203-211	1
524	Early prophylactic anticoagulation via transjugular intrahepatic route for portal vein thrombosis after splenectomy in cirrhotic portal hypertension. 2015 , 26, 1009-17	6
523	Survival and prognostic indicators of Budd-Chiari syndrome: a systematic review of 79 studies. 2015 , 9, 865-75	24
522	Pregnancy and vascular liver disease. 2015 , 5, 41-50	31
521	Acute Portal Vein Thrombosis, No Longer a Contraindication for Transjugular Intrahepatic Porto-Systemic Shunt (TIPS) Insertion. 2015 , 5, 259-61	4
520	De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system. 2015 , 27, 585-92	49
519	Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis. 2015 , 94, e496	34
518	An update on the management of Budd-Chiari syndrome: the issues of timing and choice of treatment. 2015 , 27, 200-3	37
517	Advanced Cirrhosis Combined with Portal Vein Thrombosis: A Randomized Trial of TIPS versus Endoscopic Band Ligation Plus Propranolol for the Prevention of Recurrent Esophageal Variceal Bleeding. 2015 , 276, 286-93	66
516	Postoperative Portal, Mesenteric, and Splenic Vein Thrombosis. 2015 , 261-269	
515	Budd-Chiari syndrome: investigation, treatment and outcomes. 2015 , 91, 692-7	27
5 1 4	Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. 2015 , 13, 880-3	75
513	Management of portal hypertension, Buddthiari syndrome and portal vein thrombosis. 2015 , 43, 669-673	2
512	Blood Pyrrole-Protein AdductsA Biomarker of Pyrrolizidine Alkaloid-Induced Liver Injury in Humans. 2015 , 33, 404-21	59
511	Liver Transplantation for Budd-Chiari Syndrome With Large Solitary Focal Nodular Hyperplasia of the Liver in a Patient With Essential Thrombocythemia: Case Report. [Corrected]. 2015 , 47, 2282-6	3
510	Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. 2015 , 29, 127-36	29

509	Pyrrolizidine Alkaloids: Potential Role in the Etiology of Cancers, Pulmonary Hypertension, Congenital Anomalies, and Liver Disease. 2015 , 28, 4-20	1	129
508	Portal vein thrombosis. 2015 , 19, 199-221	2	26
507	Acute portal vein thrombosis secondary to hyperhomocysteinemia with folic acid deficiency and methyl tetrahydrofolate reductase mutation: a case report and literature review. 2016 , 1, e1-e5	2	2
506	Veno-occlusive disease nurse management: development of a dynamic monitoring tool by the GITMO nursing group. 2016 , 10, 661	3	3
505	Hepatic Infarction Caused by Portal Vein Thrombophlebitis Misdiagnosed as Infiltrative Hepatic Malignancy with Neoplastic Thrombus. 2016 , 68, 156-60	1	Ĺ
504	An early decision of transjugular intrahepatic portosystemic shunt may be considered for non-malignant and non-cirrhotic portal vein thrombosis with ascites: a concise review of the theoretical possibility and practical difficulty. 2016 , 12, 1381-1383	2	2
503	Redefining Budd-Chiari syndrome: A systematic review. 2016 , 8, 691-702	2	2 5
502	A Case of Acute Budd-Chiari Syndrome Complicating Primary Antiphospholipid Syndrome Presenting as Acute Abdomen and Responding to Tight Anticoagulant Therapy. 2016 , 2016, 9565427		
501	Budd-Chiari Syndrome in a Patient with Hepatitis C. 2016 , 2016, 7493970		
500	Interventional Treatment of Severe Portal Vein Thrombosis after Living-Donor Liver Transplantation. 2016 , 83, 206-210	2	1
499	Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs. 2016 , 3,	٥	57
498	Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. 2016 , 115, 240-9	ţ	5 8
497	Thrombotic risk factors in nonmalignant and noncirrhotic patients with portal vein thrombosis: need for extensive investigation. 2016 , 28, 116-8		
496	Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. 2016 , 36, 1067-73	2	28
495	Management of portal vein thrombosis in cirrhosis: an update. 2016 , 28, 739-43	2	22
494	The use of transjugular intrahepatic portosystemic shunt should be cautious in patients without cirrhosis with obliterative portal vein thrombosis. <i>Hepatology</i> , 2016 , 64, 1374-5	11.2	
493	Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. 2016 , 43, 1154-67		28
492	Nontumoral portal vein thrombosis in patients awaiting liver transplantation. 2016 , 22, 352-65	6	52

(2016-2016)

491	Laparoscopic Splenectomy for the Elderly Liver Cirrhotic Patients With Hypersplenism: A Retrospective Comparable Study. 2016 , 95, e3012	3
490	Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis. 2016 , 28, 967-71	8
489	Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome. 2016 , 6, 37998	35
488	Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans-splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization. <i>Hepatology</i> , 2016 , 63, 1387-90	23
487	Limits of Evidence Based Medicine for rare diseases: The case of Budd-Chiari syndrome. 2016 , 48, 689	3
486	Sinusoidal obstruction syndrome. 2016 , 40, 378-85	67
485	Thrombus Resolution in Two Patients with Portal Vein Thrombosis without Anticoagulation: Do We Need to Anticoagulate Patients with Portal Vein Thrombosis?. 2016 , 25, e93-e96	2
484	Progression of Thrombus in Portal Vein, Superior Mesenteric Vein, and Splenic Vein Even on Anticoagulation in a Patient with Ascending Colonic Malignancy with Liver Metastasis: Portal Vein Thrombosis versus Portal Vein Tumor Thrombosis. 2016 , 25, e97-e99	4
483	Percutaneous Transluminal Angioplasty for Complete Membranous Obstruction of Suprahepatic Inferior Vena Cava: Long-Term Results. 2016 , 39, 1392-9	5
482	Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT. 2016 , 130, 1469-80	30
481	Treatment of non-cirrhotic, non-tumoural portal vein thrombosis. 2016 , 39, 403-410	2
480	Lymphoma and hematological conditions: II. Sickle cell hepatopathy and other hematological diseases. 2016 , 8, 6-9	1
479	Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. 2016 , 151, 574-577.e3	89
478	Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors. 2016 , 48, 1072-7	13
477	Outcomes of transjugular intrahepatic portosystemic shunt creation for flow-enabled dissolution of spleno-mesenterico-portal venous thrombosis. 2016 , 97, 1085-1093	6
476	Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice. Hepatology, 2016 , 64, 1302-1316	28
475	Portal Vein Thrombosis: Recent Advance. 2017 , 906, 229-239	14
474	Endovascular Management of Budd-Chiari Syndrome with Inferior Vena Cava Thrombosis: A 14-Year Single-Center Retrospective Report of 55 Patients. 2016 , 27, 1592-603	21

473	Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NF B , Egr1, Nrf2, MAPKs and PI3K signals. 2016 , 46, 80-89	18
472	Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China. 2016 , 44, 1152-1167	46
471	Portal vein thrombosis in cirrhotic and non cirrhotic patients: from diagnosis to treatment. 2016 , 4, 927-940	1
470	Hepatic Venous and Inferior Vena Cava Morphology No Longer a Barrier to Living Donor Liver Transplantation for Budd-Chiari Syndrome: Surgical Techniques and Outcomes. 2016 , 48, 2732-2737	6
469	Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis. 2016 , 6, 33069	7
468	Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome with diffuse occlusion of hepatic veins. 2016 , 6, 36380	21
467	Diagnosis and management of factor V Leiden. 2016 , 9, 1139-1149	28
466	A case report of simultaneous orthotopic liver transplantation and jejunectomy. 2016 , 16, 67	
465	Clonorchis sinensis ova in bile juice cytology from a patient with severe hyperbilirubinemia and portal vein thrombosis. 2016 , 44, 223-5	4
464	Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. 2016 , 28, 82-9	75
463	Hematological Issues in Liver Disease. 2016 , 32, 385-96	15
462	The ischemic liver cirrhosis theory and its clinical implications. 2016 , 94, 4-6	13
461	Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?. 2016 , 11, 1037-1040	1
460	Reply. <i>Hepatology</i> , 2016 , 64, 1375-6	
459	Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. 2016 , 36, 667-76	36
458	Non-surgical porto-mesenteric vein thrombosis is associated with worse long-term outcomes in inflammatory bowel diseases. 2016 , 4, 210-5	6
457	Guidance for the management of venous thrombosis in unusual sites. 2016 , 41, 129-43	60
456	Budd-Chiari Syndrome in Young Chinese: Clinical Characteristics, Etiology and Outcome of Recanalization from a Single Center. 2016 , 39, 557-65	5

455	[Splanchnic venous thrombosis: A monocentric study of 31 cases]. 2016 , 41, 26-35	2
454	[Treatment of non-cirrhotic, non-tumoural portal vein thrombosis]. 2016 , 39, 403-10	6
453	GI ischemia in patients with portal vein thrombosis: a prospective cohort study. 2016 , 83, 627-36	3
452	High-Output Heart Failure from a Hepatic Hemangioma With Exertion-Induced Hypoxia. 2016 , 117, 157-8	8
451	Acute idiopathic portal, mesenteric and splenic vein thrombosis. Locoregional fibrinolytic therapy. 2016 , 40, 387-9	
450	Portal vein thrombosis: When to treat and how?. 2016 , 21, 61-9	36
449	EASL Clinical Practice Guidelines: Vascular diseases of the liver. 2016 , 64, 179-202	381
448	Central obesity is associated with non-cirrhotic portal vein thrombosis. 2016 , 64, 427-432	30
447	Budd-Chiari syndrome: Focus on surgical treatment. 2017 , 47, 142-148	11
446	Diagnosis and treatment guidelines for aberrant portal hemodynamics: The Aberrant Portal Hemodynamics Study Group supported by the Ministry of Health, Labor and Welfare of Japan. 2017 , 47, 373-386	6
445	Rescue from liver transplantation: TIPSS and thrombectomy successfully treat a case of acute Budd-Chiari syndrome complicated by portal vein thrombosis. 2017 , 3, 20160059	0
444	Fulminant Hepatic Failure: Diagnosis and Management. 2017 , 229-245	
443	The problem with incidental and chronic portal vein thrombosis. 2017, 39, e29-e30	2
442	Early initiation of argatroban therapy in the management of acute superior mesenteric venous thrombosis. 2017 , 13, 1526-1534	8
441	Testing for thrombophilia in mesenteric venous thrombosis - Retrospective original study and systematic review. 2017 , 31, 39-48	16
440	Hepatic vena cava syndrome: New concept of pathogenesis. 2017 , 47, 603-615	6
439	Imaging features of non-traumatic vascular liver emergencies. 2017 , 35, 215-224	1
438	Budd-Chiari syndrome and veno-occlusive disease. 2017 , 1248-1271.e6	

437	A Comprehensive Approach to Hepatic Vascular Disease. 2017 , 37, 813-836	37
436	Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees. 2017 , 64, 639-652	18
435	Portal Vein Thrombosis in Cirrhosis. 2017 , 51, 579-585	12
434	Portal Vein Thrombosis and Cirrhosis: The Role of Anticoagulation. 2017 , 16, 158-163	3
433	The epidemiology and pathogenesis of gastrointestinal varices. 2017 , 19, 62-68	4
432	Management of venous thromboembolism in myeloproliferative neoplasms. 2017, 24, 108-114	7
431	Budd-Chiari syndrome: outcomes of endovascular intervention-A single-center experience. 2017 , 36, 209-216	7
430	Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing@Syndrome. 2017 , 5, 2324709617703672	
429	Portal vein thrombosis - a primer for the general physician. 2017 , 17, 212-219	9
428	Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult. 2017 , 20, 161-165	8
427	Gender differences in liver disease and the drug-dose gender gap. 2017 , 120, 97-108	35
426	Editor@Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). 2017 , 53, 460-510	236
425	Coagulopathy Before and After Liver Transplantation: From the Hepatic to the Systemic Circulatory Systems. 2017 , 21, 253-274	15
424	Vascular Disorders. 2017 , 143-161	
423	Management of veno-occlusive disease: the multidisciplinary approach to care. 2017 , 98, 322-329	11
422	Liver cirrhosis caused by chronic Budd-Chiari syndrome. 2017 , 96, e7425	5
421	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. 2017 , 40, 538-580	2
420	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. 2017 , 40, 538-580	13

(2017-2017)

419	Early radiological intervention and haematology screening is associated with excellent outcomes in Budd-Chiari syndrome. 2017 , 47, 1361-1367		10
418	Long-term outcomes of transjugular intrahepatic portosystemic shunt in Indian patients with Budd-Chiari syndrome. 2017 , 29, 1174-1182		15
417	Approach to thrombosis at unusual sites: Splanchnic and cerebral vein thrombosis. 2017 , 22, 529-540		6
416	Portal vein thrombosis in patients with cirrhosis. 2017 , 5, 148-156		19
415	57-Year-Old Woman With Abdominal Pain. 2017 , 92, 1278-1282		
414	Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. 2017 , 49, 1345-1352		31
413	Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. <i>Hepatology</i> , 2017 , 65, 1762-1764	11.2	21
412	Comparison of Systemic Thrombolysis Versus Indirect Thrombolysis via the Superior Mesenteric Artery in Patients with Acute Portal Vein Thrombosis. 2017 , 39, 264-269		14
411	Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort. 2017 , 27, 1227-1237		12
410	Vascular Liver Disease. 2017 , 909-934		
410	Vascular Liver Disease. 2017, 909-934 Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist@ Perspective. 2017, 5, 194-199		9
	Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian		9
409	Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist@Perspective. 2017 , 5, 194-199 Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis.		
409	Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist@ Perspective. 2017 , 5, 194-199 Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis. 2017 , 10, 152-156 Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous		12
409 408 407	Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist@ Perspective. 2017, 5, 194-199 Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis. 2017, 10, 152-156 Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient. 2017, 54, 765-770		3
409 408 407 406	Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist@ Perspective. 2017, 5, 194-199 Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis. 2017, 10, 152-156 Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient. 2017, 54, 765-770 Portal Vein Thrombosis in Patients with Liver Cirrhosis. 2017,		3
409 408 407 406 405	Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist@ Perspective. 2017, 5, 194-199 Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis. 2017, 10, 152-156 Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient. 2017, 54, 765-770 Portal Vein Thrombosis in Patients with Liver Cirrhosis. 2017, Digestive Involvement in the Antiphospholipid Syndrome. 2017, 13, 227-241 Partial spleen embolization reduces the risk of portal hypertension-induced upper gastrointestinal		3 0

401	Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction. 2017 , 16, 950-958	
400	Role of Cholelithiasis in Development of Portal Vein Aneurysm. 2018 , 131, e119	1
399	Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. 2018 , 164, 69-74	23
398	Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016. 2018 , 36, 73-91	
397	Portal-splenic-mesenteric venous thrombosis in a patient with Klinefelter syndrome. 2018 , 41, 563-565	
396	Portal Hypertensive Gastrointestinal Bleeding. 2018 , 121-136	
395	Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. 2018 , 17, e207-e216	6
394	Portal vein thrombosis after cesarean section in a patient on prolonged bed rest due to threatened preterm labor. 2018 , 6, 531-536	3
393	Budd-Chiari Syndrome and Inferior Vena Cava Obstruction: The Asian Perspective. 2018, 257-269	
392	Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. 2018 , 32, 272-279	12
391	Budd-Chiari Syndrome: The Western Perspective. 2018 , 241-255	
390	Nonviral or Drug-Induced Etiologies of Acute Liver Failure. 2018 , 22, 347-360	6
389	Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts. 2018 , 473, 3-13	18
388	Role of radiological imaging and interventions in management of Budd-Chiari syndrome. 2018 , 73, 610-624	8
387	Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. 2018 , 48, 51-58	69
386	Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study. 2018 , 38, 94-101	59
385	Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial. 2018 , 48, E107-E116	23
384	Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses. 2018 , 163, 252-259	14

(2018-2018)

383	Image-guided treatment of Budd-Chiari syndrome: a giant leap from the past, a small step towards the future. 2018 , 43, 1908-1919	4
382	Current status of portal vein thrombosis in Japan: Results of a questionnaire survey by the Japan Society for Portal Hypertension. 2018 , 48, 244-254	8
381	The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B. 2018 , 161, 7-11	5
380	CT Features of Hepatic Veno-occlusive Disease: A Meta-analysis. 2018 , 25, 328-337	15
379	Thrombosis of the Portal Venous System in Cirrhotic Patients. 2018 , 17, 1078-1080	1
378	Pattern of Vascular Involvement in Egyptian Patients with Budd-Chiari Syndrome: Relation to Etiology and Impact on Clinical Presentation. 2018 , 17, 638-644	4
377	Acute intestinal ischaemia from a portal vein thrombosis in a young female smoker on an oral contraceptive. 2018 , 2018,	2
376	Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture. 2018 , 24, 4419-4427	11
375	Portal Hypertension Related to Bleeding. 2018 , 233-261.e3	1
374	Timing of Transjugular Intrahepatic Portosystemic Stent-shunt in Budd-Chiari Syndrome: A UK Hepatologist@Perspective. 2018 , 6, 97-104	5
373	Portal-splenic-mesenteric venous thrombosis in a patient with Klinefelter syndrome. 2018 , 41, 563-565	
372	Splanchnic Vein Thrombosis in Cirrhosis - Areas Still in the Shadow. 2018 , 9, 211	
371	Transjugular intrahepatic portosystemic shunt for the prevention of recurrent esophageal variceal bleeding in patients with cavernous transformation of portal vein. 2018 , 17, 517-523	7
370	The impact of portal vein thrombosis on the prognosis and liver function of nonmalignant cirrhotic patients. 2018 , 53, 1340-1346	2
369	Clinical Considerations of Drug-Induced Hepatotoxicity. 2018 , 608-624	
368	Vascular Disorders. 2018 , 636-672	5
367	The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis. 2018 , 30, 1187-1193	28
366	Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. 2018 , 5, e441-e449	13

365	An enigmatic case presentation of Budd-Chiari syndrome with pulmonary embolism: An unusual syndrome with an uncommon complication. 2018 , 48, 16-21	
364	Short-Term Outcome of Patients with Cirrhosis and Concurrent Portal Cavernoma Presenting with Acute Variceal Bleeding. 2018 , 2018, 9491856	
363	Acute Portal Vein Thrombosis: Current Trends in Medical and Endovascular Management. 2018 , 35, 198-202	13
362	Uncommon Presentations of Idiosyncratic Drug-Induced Liver Injury. 2018 , 17, 254-259	
361	Catheter-directed thrombolysis combined with anticoagulation for acute extensive portal vein thrombosis: Our experience. 2018 , 19, 635-640	1
360	Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. 2018 , 2018, 8432781	40
359	Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids. 2018 , 2018, 9804582	1
358	Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis. 2018 , 167, 96-103	17
357	Direct Intrahepatic Portosystemic Shunt in Budd-Chiari Syndrome: A Case Report and Review of the Literature. 2018 , 2018, 9261268	1
356	Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist@ Perspective. 2018 , 6, 6-10	2
355	Portal Vein Thrombosis after Endovascular Embolization of Splenic Artery for a Symptomatic Arterioportal Fistula: A Case Report and Literature Review. 2018 , 53, 270.e7-270.e12	2
354	Vascular Disorders of the Liver. 2018 , 467-483	
353	Vascular Disorders of the Liver and Extrahepatic Portal Hypertension. 2018 , 209-230	1
352	DDX24 Mutations Associated With Malformations of Major Vessels to the Viscera. <i>Hepatology</i> , 2019 , 69, 803-816	5
351	Acute Portal Vein Thrombosis Predicts Concomitant Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients. 2019 , 50, 759-762	2
350	Current concepts in portal vein thrombosis: etiology, clinical presentation and management. 2019 , 44, 3453-3462	7
349	Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index. 2019 , 25, 1747-1755	8
348	Endoscopic Cyanoacrylate Injection with Lauromacrogol for Gastric Varices: Long-Term Outcomes and Predictors in a Retrospective Cohort Study. 2019 , 29, 1135-1143	5

347	Usefulness of Venous Pressure Measurement in Endovascular Treatment of Budd-Chiari Syndrome: A Retrospective Cohort Study. 2019 , 58, 2923-2929	О
346	Vascular Liver Disease. 2019 , 329-344	
345	The Liver in Systemic Illness. 2019 , 361-396	O
344	Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial. 2019 , 4, 686-697	19
343	Consult for Portal Vein Thrombosis. 2019 , 14, 74-77	1
342	Transjugular intrahepatic portosystemic shunt prevents rebleeding in cirrhotic patients having cavernous transformation of the portal vein without improving their survival. 2019 , 20, 89-96	4
341	Splanchnic Vein Thrombosis: Current Perspectives. 2019 , 15, 449-461	30
340	Delayed development of portal vein thrombosis in a patient initially detected with portal venous gas and pneumatosis intestinalis: a case report. 2019 , 6, 419-422	2
339	A stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia. 2019 , 50, 1049-1058	12
338	Case 4: Large-Volume Hematemesis in a 16-year-old Boy. 2019 , 40, 538-542	
337	Pylephlebitis treated with apixaban. 2019 , 47, 192-195	3
337	Pylephlebitis treated with apixaban. 2019 , 47, 192-195 Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. 2019 , 34, 634-642	3
	Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal	
336	Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. 2019 , 34, 634-642 A case of antiphospholipid syndrome presenting cryptogenically as Budd-Chiari syndrome, then	41
336 335	Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. 2019, 34, 634-642 A case of antiphospholipid syndrome presenting cryptogenically as Budd-Chiari syndrome, then fulminantly as Libman-Sacks endocarditis. 2019, 12,	41 1
336 335 334	Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. 2019, 34, 634-642 A case of antiphospholipid syndrome presenting cryptogenically as Budd-Chiari syndrome, then fulminantly as Libman-Sacks endocarditis. 2019, 12, Porta hepatis abscess and portal vein thrombosis following ingestion of a fishbone. 2019, 12, Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical	41 1 2
336 335 334 333	Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. 2019, 34, 634-642 A case of antiphospholipid syndrome presenting cryptogenically as Budd-Chiari syndrome, then fulminantly as Libman-Sacks endocarditis. 2019, 12, Porta hepatis abscess and portal vein thrombosis following ingestion of a fishbone. 2019, 12, Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. 2019, 98, 1733-1742	41 1 2 3

329	Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome. 2019 , 9, 2179	3
328	Regional Differences in Budd-Chiari Syndrome and the Role of Spectral CT for the Assessment of Therapeutic Response. 2019 , 26, 467-468	
327	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. 2019 , 189, 1159-1175	14
326	Porto-sinusoidal vascular disease: proposal and description of a novel entity. 2019 , 4, 399-411	66
325	Diagnosis of Portal Vein Thrombosis. 2019 , 481-484	
324	Treatment of the Portal Vein Thrombosis. 2019 , 485-489	
323	Direct oral anticoagulant successfully used to treat an adult nephrotic patient complicated with portal vein thrombosis. 2019 , 8, 134-138	5
322	Hepatic Venous Outflow Syndromes and Splanchnic Venous Thrombosis. 2019 , 645-661	
321	Hypothesis: Can drug-loaded platelets be used as delivery vehicles for blood-brain barrier penetration?. 2019 , 125, 75-78	5
320	Contrast-Enhanced Ultrasonography in the Diagnosis of Portal Vein Thrombosis: A Pictorial Review. 2019 , 35, 311-315	2
319	Anticoagulation and Transjugular Intrahepatic Portosystemic Shunting for Treatment of Portal Vein Thrombosis in Cirrhosis: A Systematic Review and Meta-Analysis. 2019 , 25, 1076029619888026	1
318	Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients. 2019 , 19, 217	10
317	Budd-Chiari Syndrome in a Patient With Simultaneous Diagnosis of Hepatic Sarcoidosis and Nodular Regenerative Hyperplasia. 2019 , 6, e00200	0
316	Escalating interventional recanalization therapy in non-cirrhotic, non-malignant acute portal vein thrombosis. 2019 , 31, 1584-1591	8
315	Insulin Resistance and Portal Vein Thrombosis. 2019 , 37, 183-187	Ο
314	Abdominal pain, nausea, vomiting, and ascites in a 14-year-old girl with systemic lupus erythematosus: Answers. 2019 , 34, 431-433	
313	Ascitic cholesterol is superior to serum-ascites albumin gradient in the detection of non-portal hypertensive ascites and the diagnosis of mixed ascites. 2019 , 49, 91-98	5
312	Defibrotide for the treatment of severe hepatic sinusoidal obstruction syndrome: a single-centre experience. 2019 , 26, 343-346	

(2020-2019)

311	Characterization of Malignant Portal Vein Thrombosis with Contrast-Enhanced Ultrasonography. 2019 , 45, 50-55	10
310	Percutaneous portal vein recanalization using self-expandable nitinol stents in patients with non-cirrhotic non-tumoral portal vein occlusion. 2019 , 100, 147-156	16
309	Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort. 2019 , 34, 1088-1092	15
308	Venous thrombosis in unusual sites: A practical review for the hematologist. 2019 , 102, 53-62	13
307	Venous Thromboses at Unusual Sites. 2019 , 300-337	1
306	Assessment of hepatic sinusoidal obstruction syndrome with intravoxel incoherent motion diffusion-weighted imaging: An experimental study in a rat model. 2020 , 51, 81-89	5
305	I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. 2020 , 43, 196-203	3
304	Dabigatran as an oral anticoagulant in patients with Budd-Chiari syndrome post-percutaneous endovascular intervention. 2020 , 35, 654-662	17
303	Ascitic fluid total protein, a useful marker in non-portal hypertensive ascites. 2020 , 35, 271-277	4
302	Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction. 2020 , 35, 1049-1056	2
301	Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational study. 2020 , 35, 1215-1222	4
300	Prognostic Factors for Acute Transjugular Intrahepatic Portosystemic Shunt Occlusion Using Expanded Polytetrafluoroethylene-Covered Stent. 2020 , 65, 3032-3039	3
299	Changes in the distribution of etiologies of cirrhosis among patients referred for liver transplantation over 11 years in Iran. 2020 , 32, 844-850	1
298	Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study. 2020 , 32, 1168-1178	5
297	Portal vein thrombosis prevalence and mortality among alcoholic cirrhosis in a nationwide inpatient cohort. 2020 , 32, 1160-1167	3
296	Exploration of interventional therapy strategy for portal vein occlusion: a case series study. 2020 , 32, 507-516	4
295	Acute-on-Chronic Liver Failure in Budd-Chiari Syndrome: Profile and Predictors of Outcome. 2020 , 65, 2719-2729	6
294	Clinical characteristics and outcomes of patients with hepatic veno-occlusive disease induced by Gynura segetum: A retrospective study. 2020 , 18, 434-440	1

293	Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy. 2020 , 1	О
292	Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. 2020 , 40, 2110-2116	114
291	Afectacili del higado en las enfermedades sistinicas y cardiovasculares. 2020 , 13, 268-276	
290	A Large Tortuous Umbilical Cord with Superficial Abdominal Wall Varicose Veins in a Newborn. 2020 , 21, e774-e777	
289	Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction. 2020 , 44, 491-496	3
288	Controversies in the Management of Portal Vein Thrombosis in Liver Cirrhosis. 2020 , 9,	1
287	Placement of a transjugular intrahepatic portosystemic shunt in addition to recanalization of acute and chronic portomesenteric vein occlusions - a retrospective evaluation. 2020 , 9, 2058460120964074	2
286	Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. 2020 , 32, 1395-1400	14
285	Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders. 2020 , 9,	1
284	Management of acute extensive portal vein thrombosis: the complexity and morbidity. 2020 , 13,	O
283	[30 Years of Transjugular Intrahepatic Portosystemic Shunt (TIPS): casting a retrospective glance and future perspectives]. 2020 , 58, 877-889	5
282	Transjugular intrahepatic portosystemic shunt in cirrhotic patients with portal vein thrombosis. 2020 , 32, 762-763	2
281	Causes and Management of Non-cirrhotic Portal Hypertension . 2020 , 22, 56	6
280	Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis. 2020 , 10,	2
279	Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. 2021 , 42, 1212-1222	15
278	Predicting the risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. 2020 , 6, e04677	1
277	Hereditary Hemorrhagic Telangiectasia and Refractory Ascites. 2020 , 7, e00458	
276	The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis. 2020 , 31, 213-218	8

(2021-2020)

275	A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment. 2020 , 52, 329-339	14
274	Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions. 2020 , 9,	14
273	Budd-Chiari Syndrome: An Uncommon Cause of Chronic Liver Disease that Cannot Be Missed. 2020 , 24, 453-481	4
272	Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. 2020 , 26, 1770-1779	12
271	Hepatic veno-occlusive disease may be a rare characteristic of hepatic involvement in systemic amyloidosis: case report and literature review. 2020 , 48, 300060520904857	
270	Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study. 2020 , 20, 30	9
269	Therapeutic and Prophylactic Anticoagulation in Cirrhosis Patients. 2020 , 19, 119-127	
268	Coagulation testing and management in liver disease patients. 2020 , 36, 169-176	2
267	Non-Gaussian Diffusion Models and T rho Quantification in the Assessment of Hepatic Sinusoidal Obstruction Syndrome in Rats. 2020 , 52, 1110-1121	1
266	Treatment of unusual thrombotic manifestations. 2020 , 135, 326-334	14
266 265	Treatment of unusual thrombotic manifestations. 2020 , 135, 326-334 Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. 2021 , 38, 495-520	14
	Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and	
265	Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. 2021 , 38, 495-520	
265 264	Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. 2021 , 38, 495-520 Vascular Disorders. 2021 , 268-287	14
265 264 263	Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. 2021, 38, 495-520 Vascular Disorders. 2021, 268-287 An Update on the Management of Budd-Chiari Syndrome. 2021, 66, 1780-1790	14
265 264 263 262	Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. 2021, 38, 495-520 Vascular Disorders. 2021, 268-287 An Update on the Management of Budd-Chiari Syndrome. 2021, 66, 1780-1790 Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. 2021, 74, 89-95 Long-Term Outcomes of Endovascular Interventions in More than 500 patients with Budd-Chiari	14 8 9
265 264 263 262 261	Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. 2021, 38, 495-520 Vascular Disorders. 2021, 268-287 An Update on the Management of Budd-Chiari Syndrome. 2021, 66, 1780-1790 Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. 2021, 74, 89-95 Long-Term Outcomes of Endovascular Interventions in More than 500 patients with Budd-Chiari Syndrome. 2021, 32, 61-69.e1 Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. 11.2	14 8 9 2

257	Benign and malignant mimickers of infiltrative hepatocellular carcinoma: tips and tricks for differential diagnosis on CT and MRI. 2021 , 70, 33-45	6
256	Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. 2021 , 137, 1233-1240	10
255	Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: A case report. 2021 , 20, 100138	4
254	How to Manage Sleeve Complications: Portal/Mesenteric Vein Thrombosis. 2021 , 517-522	
253	Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China. 2021 , 9, 11	1
252	Liver Transplantation in the Setting of Non-malignant Portal Vein Thrombosis. 2021 , 131-156	
251	Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. 2021 , 25, 200-207	0
250	Fibrosis and hepatic regeneration mechanism 2022 , 7, 9	
249	Systematic Review of Thrombolysis Therapy in the Management of Non-Cirrhosis-Related Portal Vein Thrombosis. 2021 , 25, 1579-1590	6
248	Transjugular Intrahepatic Portosystemic Shunt for Non-malignant Portal Vein Thrombosis. 2021 , 117-129	
247	Computational fluid dynamics simulation of time-resolved blood flow in Budd-Chiari syndrome with inferior vena cava stenosis and its implication for postoperative efficacy assessment. 2021 , 82, 105256	O
246	Clinical Predictors of Morbidity and Mortality in Hospitalized Pediatric Patients With Ascites. 2021 , 73, 86-92	1
245	Clostridium Difficile and COVID-19: Novel Risk Factors for Acute Portal Vein Thrombosis. 2021 , 2021, 8832638	4
244	Metastatic Infiltration of Anaplastic Carcinoma of the Pancreas Into the Portal Venous System: A Masquerading Cause of Expansive Portal Venous Thrombosis. 2021 , 22, e929678	
243	A Rare Cause of Cholestasis Related to Polycystic Liver Disease 2021 , 28, 443-445	
242	Updated recommendations for the treatment of venous thromboembolism. 2021 , 56, 6-16	O
241	Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis. 2021 , 45, 101649	О
240	Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease. 2021 , 37, 355-360	1

239	Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data. 2021 , 14, 49-65	3
238	Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis. 2021 , 2021, 8859602	2
237	Budd-Chiari syndrome associated with liver cirrhosis: A case report. 2021 , 9, 2937-2943	
236	Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes. 2021 , 5, e12500	O
235	Transhepatic Pharmacomechanical Thrombectomy of Symptomatic Acute Noncirrhotic, Nonmalignant Portomesenteric Venous Thrombosis: Midterm Results. 2021 , 217, 418-425	Ο
234	Portal vein thrombosis: A concise review (Review). 2021 , 22, 759	O
233	Quantitative CT assessment by histogram and volume ratio in pyrrolizidines alkaloids-induced hepatic sinusoidal obstruction syndrome. 2021 , 138, 109632	Ο
232	Successful defibrotide treatment of a patient with veno-occlusive disease after living-donor liver transplantation: A case report. 2021 , 100, e26463	2
231	Viscoelastic tests in liver disease: where do we stand now?. 2021 , 27, 3290-3302	4
230	Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). 2021 , 15, 531-567	3
229	Progress in clinical diagnosis and treatment of cavernous transformation of the portal vein. 2021 , 29, 662-669	
228	Splanchnic vein thrombosis: Clinical manifestations, risk factors, management, and outcomes. 2021 , 202, 90-95	2
227	Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. 2021 , 27, 535-552	2
226	Timing of treatment and outcome of Budd-Chiari syndrome. 2021 , 20210284	
225	Sinusoidal Obstruction Syndrome.	
224	Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women. 2021 , 46, 101756	
223	Evaluation of liver histopathological findings of COVID-19 by minimally invasive autopsies. 2021,	1
222	Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. 2021 , 51, 1064-1072	О

221	Usage of Direct Acting Oral Anticoagulants in Cirrhotic and Non-Cirrhotic Portal Vein Thrombosis: A Systematic Review. 2021 , 13, e16922	1
220	Is antivitamin K reversal required in patients with cirrhosis undergoing liver transplantation?. 2021 , 61, 3008-3016	Ο
219	Portal Vein Thrombosis in a Patient With Methylenetetrahydrofolate Reductase Gene Mutation and Normal Homocysteine Levels. 2021 , 13, e18225	1
218	Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review. 2021 , 22, 506-519	
217	Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease. 2021 , 11, 19275	0
216	Portal vein thrombosis in patients with chronic liver diseases: From conventional to quantitative imaging. 2021 , 142, 109859	O
215	Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience. 2021 , 17, 619-629	
214	Open Cardiac Surgery in a Patient With Chronic Budd-Chiari Syndrome. 2021 , 35, 3042-3044	
213	Focusing the Controversies in Budd-Chiari Syndrome Management. 2022 , 1,	
212	The Albumin-bilirubin Score Detects Changes in the Liver Function During Treatment for Budd-Chiari Syndrome: A Retrospective Observational Study. 2021 ,	O
211	Limited added value of Doppler ultrasound of the liver after recent contrast-enhanced computed tomography. 2021 , 46, 2567-2574	
211 210		
	tomography. 2021 , 46, 2567-2574	
210	Impact of Non-malignant Portal Vein Thrombosis on Outcomes of Liver Cirrhosis. 2021 , 77-87	2
210	Impact of Non-malignant Portal Vein Thrombosis on Outcomes of Liver Cirrhosis. 2021, 77-87 Thrombolysis for Non-malignant Portal Vein Thrombosis. 2021, 103-115	2
210 209 208	Impact of Non-malignant Portal Vein Thrombosis on Outcomes of Liver Cirrhosis. 2021, 77-87 Thrombolysis for Non-malignant Portal Vein Thrombosis. 2021, 103-115 Sinusoidal Endothelial Cells. 2011, 97-107 Hepatic Vascular Pathology After Hematopoietic Cell Transplantation: Sinusoidal Obstruction	
210 209 208 207	Impact of Non-malignant Portal Vein Thrombosis on Outcomes of Liver Cirrhosis. 2021, 77-87 Thrombolysis for Non-malignant Portal Vein Thrombosis. 2021, 103-115 Sinusoidal Endothelial Cells. 2011, 97-107 Hepatic Vascular Pathology After Hematopoietic Cell Transplantation: Sinusoidal Obstruction Syndrome, Focal Nodular Hyperplasia, and Nodular Regenerative Hyperplasia. 2011, 149-163	1

203	Controversies in the Management of Buddthiari Syndrome. 2020 , 245-252	2
202	Liver. 2011 , 857-980	3
201	Vascular Diseases of the Liver. 2010 , 1371-1382.e3	1
200	Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer. 2019 , 74, 675-677	2
199	Venous thrombosis of the liver: current and emerging concepts in management. 2020 , 225, 54-69	4
198	Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. 2021 , 33, 911-916	3
197	Use of the AngioJet percutaneous thrombectomy system for the treatment of acute Budd-Chiari syndrome. 2013 , 2013,	1
196	Diffuse cholangiocarcinoma presenting with hepatic failure and extensive portal and mesenteric vein thrombosis. 2015 , 2015,	1
195	Anticoagulation in the treatment of portovenous emboli after cyanoacrylate injection for a bleeding gastric varix. 2015 , 56, e14-6	1
194	A single-center retrospective study: Clinical features of different types of Budd-Chiari syndrome in Chinese patients in the Hubei area. 2018 , 26, 80-89	2
193	A study of the different parameters in acute and chronic Buddthiari syndrome. 2020, 10,	1
192	Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis: a hypothesis. 2012 , 18, HY37-41	12
191	Diagnostic utility of computed tomographic angiography in dogs with portal vein thrombosis. 2020 , 82, 1421-1427	3
190	Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants. 2019 , 7, 154-164	21
189	Hereditary Hemorrhagic Telangiectasia With Liver Vascular Malformation Presenting With High-Output Heart Failure. 2014 , 2, 16-7	3
188	Budd-Chiari Syndrome. 2017 , 118, 69-80	17
187	Hemostasis, bleeding and thrombosis in liver disease. 2017 , 3,	23
186	The effect of Salvia miltiorrhiza in a mouse model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum. 2019 , 111, 823-827	3

185	Specific alterations in gut microbiota are associated with prognosis of Budd-Chiari syndrome. 2018 , 9, 3303-3320	6
184	Epidemiological Characteristics and Etiology of Budd-Chiari Syndrome in Upper Egypt. 2020 , 11, 515-524	2
183	Sādrome de Budd-Chiari: etiologā, manejo y resultados en una cohorte de 35 pacientes del Hospital Pablo Tobā Uribe. 2020 , 35, 280-286	1
182	What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. 2012 , 18, 5014-20	32
181	Prognostic factors in non-malignant and non-cirrhotic patients with portal cavernoma: an 8-year retrospective single-center study. 2013 , 19, 7447-54	6
180	Liver diseases in pregnancy: diseases not unique to pregnancy. 2013 , 19, 7630-8	16
179	Study of liver cirrhosis over ten consecutive years in Southern China. 2014 , 20, 13546-55	32
178	Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder. 2014 , 20, 14495-9	3
177	Budd-Chiari syndrome: a single-center experience. 2014 , 20, 16236-44	23
176	Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome. 2015 , 21, 2413-8	9
175	One step minilaparotomy-assisted transmesenteric portal vein recanalization combined with transjugular intrahepatic portosystemic shunt placement: A novel surgical proposal in pediatrics. 2017 , 23, 2811-2818	2
174	Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: A single-center study. 2017 , 23, 629-637	6
173	Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis. 2018 , 24, 4482-4488	9
172	Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. 2019 , 25, 3753-3763	23
171	Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. 2019 , 25, 4437-4451	28
170	Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease. 2020 , 26, 3000-3011	4
169	Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: A comprehensive review. 2020 , 26, 5060-5073	3
168	Small for size liver remnant following resection: prevention and management. 2014 , 3, 303-12	16

(2010-2019)

167	Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis?. 2019 , 11, 613-618	4
166	Budd-Chiari syndrome management: Lights and shadows. 2011 , 3, 262-4	29
165	Portal vein thrombosis in liver cirrhosis. 2014 , 6, 64-71	44
164	Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient. 2014 , 6, 532-7	5
163	Liver cirrhosis in hepatic vena cava syndrome (or membranous obstruction of inferior vena cava). 2015 , 7, 874-84	13
162	Budd-Chiari Syndrome: an unnoticed diagnosis. 2015 , 5, 17-25	2
161	Liver transplant in Budd-Chiari syndrome: a single-center experience in Saudi Arabia. 2014 , 12, 52-4	4
160	Utility of Transjugular Intrahepatic Portosystemic Shunt Placement for Maintaining Portal Vein Patency in Candidates on Wait Lists Who Develop Thrombus. 2020 , 18, 808-813	1
159	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 2021 , 19, 541-565	74
158	Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome. 2021 , 11, 730091	O
157	A Case of Idiopathic Portal Vein Thrombosis in an Immunocompetent Female. 2021 , 13, e18817	
156	MR imaging features and long-term evolution of benign focal liver lesions in Budd-Chiari syndrome and Fontan-associated liver disease. 2021 ,	Ο
155	A Case Series of Budd-Chiari Syndrome in Nigerian Patients: Diagnosis, Associations, Management, and Outcomes.	
154	Portal Vein Thrombosis: Diagnosis and Endovascular Management. 2021 ,	O
153	Management of portal vein thrombosis in cirrhotic patients. 2009 , 1, e2009014	13
152	Foie et contraception orale. 2010 , 239-244	
151	Vascular Disorders. 2010 , 233-247	
150	Thromboses portales. 2010 , 181-193	

149	Budd-Chiari Syndrome - Hepatic Venous Outflow Tract Obstruction. 141-150	
148	Liver Endothelial Cells: Hemostasis, Thrombosis, and Hepatic Vascular Diseases. 2011 , 3-23	
147	Budd-Chiari Syndrome. 2011 , 197-211	
146	Hepatic Encephalopathy in Connection With Budd-Chiari Syndrome due to Infection With Echinococcus Multilocularis: A Case Report. 2011 , 4, 127-130	1
145	Histological Diagnosis. 2011 , 103-123	
144	Vascular Disorders. 2011 , 134-153	1
143	Congenital Hepatic Vascular Malformations. 2011 , 213-227	
142	Portal Vein Thrombosis. 2011 , 183-196	1
141	Portal and Splenic Vein Thrombosis. 2012 , 812-821	
140	Liver Involvement in Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia). 2012 , 822-833	
139	Rare Indications for Liver Transplantation. 145-154	
138	Vascular Disorders of the Liver. 786-792	
137	B. 2013 , 142-196	
136	Hepatic Complications of Hematopoietic Stem Cell Transplantation. 286-293	
135	Hemodynamic and Perfusion-Related Disorders. 2014 , 263-302	
134	Radiology of the Liver in Children. 2014 , 85-105	
133	Vascular Liver Disease. 2014 , 403-422	
132	Bildgebung bei Venenerkrankungen. 2014 , 377-401	

Budd-Chiari-Syndrom. 2014, 1-5 131 Variceal Bleeding in Patients with Vascular Liver Disease. 2014, 245-262 130 Fulminant Hepatic Failure: Diagnosis and Management. 2014, 1-18 129 Akutes und chronisches Leberversagen. 2015, 829-842 128 Geferkrankungen der Leber. 2015, 379-387 127 Pfortaderthrombose. 2015, 1-6 126 Intensivtherapie bei akutem und chronischem Leberversagen. 2015, 1-24 125 Vascular Diseases of the Liver. 2171-2182 124 Vascular Disorders. 2016, 251-266 123 Management of Early Post-transplant Portal Vein Thrombosis: Results of Interventional Techniques Versus Surgical. 2016, 359-367 Budd-Chiari-Syndrom. 2016, 25-29 121 Fulminant Hepatic Failure: Diagnosis and Management. 2016, 1-18 120 Pfortaderthrombose. 2016, 31-35 119 Extrahepatic Portal Vein Obstruction (EHPVO) and Idiopathic Portal Hypertension: East Versus 118 West. 2016, 377-395 Pfortaderthrombose. 2016, 31-35 117 116 Bleeding and Thrombosis in a Cancer Patient. 2016, 395-402 Unmet Clinical Needs of Antithrombotic Treatment in BCR/ABL-Negative Myeloproliferative 115 Neoplasms. 2016, 379-393 How should I treat Budd-Chiari syndrome after liver transplantation with inferior vena cava 114 occlusion?. **2016**, 12, 124-8

113	Miscellaneous Disorders: Pregnancy-Associated Liver Disorders, Vascular Disorders, Granulomatous Diseases, and Amyloidosis. 2017 , 405-451	
112	Portal Hypertension. 2017, 455-468	
111	Portal Vein Thrombosis in Adult Omani Patients: A Retrospective Cohort Study. 2017, 32, 522-527	
110	Management of Intra-abdominal Thrombosis. 205-215	
109	Budd-Chiari Syndrome and Sinusoidal Obstruction Syndrome. 2018 , 649-657.e4	
108	Portal and Splenic Vein Thrombosis. 2018, 658-666.e3	Ο
107	Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: A US Hepatologist@ Perspective. 2018 , 6, 1-5	1
106	Experience of Liver Transplant in Patients Diagnosed with Budd-Chiari Syndrome. 2018 , 16, 177-181	1
105	A Case of Live Donor Liver Transplantation in Acute-on-Chronic Liver Failure with Budd-Chiari Syndrome: Donor and Recipient with Antiphospholipid Antibody Syndrome. 2018 , 19, 767-772	4
104	Extrahepatic Portal Vein Obstruction. 2019 , 569-577	
103	Correlation analysis of collagen proportionate area in Budd-Chiari syndrome: A preliminary clinicopathological study. 2019 , 7, 130-136	
102	Modified calcium from waste by product of crustaceans (polymesoda erosa)shell as alternative sunscreen materials. 2019 , 8, 180-183	Ο
101	Histopathology of Hepatic Sinusoidal Obstruction Syndrome After Neoadjuvant Oxaliplatin-Based Chemotherapy. 2019 , 20, 39-46	
100	Budd-Chiari syndrome managed with percutaneous recanalization: Long-term outcome and comparison with medical therapy. 2019 , 8, 74-81	Ο
99	Anticoagulation in the Hospitalized Patient with Decompensated Cirrhosis: Management of a Delicate Balance. 2020 , 219-236	
98	Single-Center Retrospective Study of Clinical and Laboratory Features That Predict Survival of Patients With Budd-Chiari Syndrome After Liver Transplant. 2019 , 17, 665-672	
97	Extraintestinal Manifestations of Inflammatory Bowel Disease. 2020 , 177-213	1
96	Anticoagulation for Buddthiari Syndrome. 2020 , 131-145	

Liver Transplantation for Budd Thiari Syndrome. 2020, 181-187 95 Buddthiari Syndrome and Myeloproliferative Neoplasms. 2020, 73-88 94 Surgery for Budd Chiari Syndrome. 2020, 171-179 93 Slidrome de Budd-Chiari en paciente pluripatolgico con colitis ulcerosa... ¿y algo ml?. 2019, 4, 132-133 92 Vascular Disorders of the Liver. 2020, 117-128 91 Liver histopathology in COVID 19 infection is suggestive of vascular alteration. 90 The protective effect of sildenafil on liver sinusoidal obstructive syndrome after oxaliplatin-based 89 chemotherapy: An experimental animal study. 2020, 4, 587-591 88 Vascular Liver Diseases. 2021, 295-322 Outcomes of combination treatment with MARS and TIPS for hepatic veno-occlusive disease: a 87 1 report of 12 cases. 2020, 48, 300060520980877 Diagnosis and management of extrahepatic oesophageal variceal bleed in children in a low 86 resourced setting. 2020, 54, 274-278 Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver 85 8 cirrhosis: a systematic review and meta-analysis. 2021, 34, 104-110 SBdrome de Budd Chiari de apariciB en el puerperio: Reporte de caso y revisiB de la literatura. 84 **2019**, 34, 297-302 83 Thrombophilia in hepatocellular carcinoma. 2019, 9, Portal Vein Thrombosis in Liver Transplantation and in Non-transplant Treatment. 2020, 157-166 82 Vascular Diseases of the Liver. 2020, 693-699 81 80 Research Progress on Etiology of Cirrhosis with Portal Vein Thrombosis. 2020, 10, 185-190 Talking About Rare Diseases. 2020, 1-86 79 Vaskulle Erkrankungen und Durchblutungsstllungen. 2020, 43-62 78

77	Clinical case of chronic portal vein thrombosis. 2020 , 27-41	
76	Presence of ascites at presentation is associated with absence of long term response amongst patients with Budd-Chiari syndrome when treated with medical therapy alone: A single centre real life experience. 2021,	O
75	Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. 2021 , 11, 21743	Ο
74	Portal Vein Thrombosis: Recent Advance. 2016 ,	
73	Pre-transplant Liver Disorders: Post-transplant Impact on Developing Venocclusive Disease/Sinusoidal Obstruction Syndrome and Other Hepatic Problems. 2019 , 157-168	
72	IR Management of Budd [Ihiari Syndrome. 2021 , 107-118	
71	Correlation between Primary Myelofibrosis and the Association of Portal Thrombosis with Portal-Biliary Cavernoma: US, MDCT, and MRI Features. 2021 , 04, 008-013	
70	Nontumoral Portal Vein Thrombosis: A Challenging Consequence of Liver Cirrhosis. 2020 , 8, 432-444	4
69	Ultrasonic Evaluation of Spontaneous Portosystemic Shunts in Patients with Budd-Chiari Syndrome. 2020 , 17,	
68	Research status of Budd-Chiari syndrome in China. 2014 , 7, 4646-52	7
67	Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction. 2015 , 8, 9071-8	5
66	Single-center study: evaluation of sonography in Budd-Chiari syndrome. 2021 ,	
65	Portal Hypertension in Children. 2022 , 953-981	
64	Idiopathic portal vein thrombosis not related to hepatic disease or malignancy. 2021, 14,	
63	Antithrombotic Therapy and Liver Disease. 2022 , 249-265	
62	Narrative review of portal vein thrombosis in cirrhosis: pathophysiology, diagnosis, and management from an interventional radiology perspective 2022 , 12, 135-146	0
61	Treatment of portal vein thrombosis: an updated narrative review. 2021,	1
60	Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study 2022 , 17, e0261671	2

59	A Case of Portal Vein Thrombosis in a Patient With Methylenetetrahydrofolate Reductase A1298C Polymorphism 2022 , 14, e21743	
58	A Case of Portal Vein Thrombosis Induced by Congenital Protein C Deficiency. 2022 , 63, 62-68	
57	Thrombose porte: Quand prescrire un traitement anticoagulant?. 2022,	
56	Treatment of Atypical Clots 2022 , 42, 10-18	
55	Liver Growth and Portal Hypertension Improvement After Percutaneous Recanalization of Chronic Portal Vein Thrombosis in Non-Cirrhotic Participants 2022 , 1	О
54	Optimal Treatment for Patients With Cavernous Transformation of the Portal Vein 2022 , 9, 853138	O
53	Validation of color Doppler ultrasound and computed tomography in the radiologic assessment of non-malignant acute splanchnic vein thrombosis 2021 , 16, e0261499	О
52	Differentiation of malignant from non-malignant portal vein thrombosis in liver cirrhosis: the challenging dilemma. 2021 , 11,	0
51	Usefulness of Imaging and Biological Tools for the Characterization of Portal Vein Thrombosis in Hepatocellular Carcinoma. 2022 , 12, 1145	
50	Pediatric Portal Hypertension: Etiology and Management.	
49	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis.	1
49	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Drug-Induced Liver Injury. 2022, 237-263	1
		1
48	Drug-Induced Liver Injury. 2022 , 237-263 Hepatic Necrosis Mimicking Infiltrative Masses in Acute Budd-Chiari Syndrome With Hereditary	1
48	Drug-Induced Liver Injury. 2022, 237-263 Hepatic Necrosis Mimicking Infiltrative Masses in Acute Budd-Chiari Syndrome With Hereditary Protein C Deficiency. 2022, 9, e00802	1
48 47 46	Drug-Induced Liver Injury. 2022, 237-263 Hepatic Necrosis Mimicking Infiltrative Masses in Acute Budd-Chiari Syndrome With Hereditary Protein C Deficiency. 2022, 9, e00802 Portal vein thrombosis as a manifestation of post-COVID syndrome: a case study. 2022, 23, 69-77 Chronic abdominal pain and Budd-Chiari Syndrome: A relentless quest for an underlying neoplastic	1
48 47 46 45	Drug-Induced Liver Injury. 2022, 237-263 Hepatic Necrosis Mimicking Infiltrative Masses in Acute Budd-Chiari Syndrome With Hereditary Protein C Deficiency. 2022, 9, e00802 Portal vein thrombosis as a manifestation of post-COVID syndrome: a case study. 2022, 23, 69-77 Chronic abdominal pain and Budd-Chiari Syndrome: A relentless quest for an underlying neoplastic etiology.	

41	Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis. 1-11	
40	Percutaneous transluminal angioplasty for symptomatic hepatic vein-type Budd-Chiari syndrome: feasibility and long-term outcomes. 2022 , 12,	
39	Hepatic venous pressure gradient in sinusoidal obstruction syndrome: diagnostic value and link with histological lesions. 2022 , 100558	1
38	Acute mesenteric ischemia secondary to oral contraceptive-induced portomesenteric and splenic vein thrombosis: A case report. 10, 10629-10637	O
37	Prevalence of portal vein thrombosis in patients with chronic liver disease using triphasic computed tomography scan as diagnostic modality: A study in Jos, North-Central, Nigeria. 2020 , 1, 43	0
36	Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma. Publish Ahead of Print,	O
35	Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis. 2022 , 12,	0
34	Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation and the Management of Portal Vein Thrombosis. 2022 , 4, 147-156	O
33	Impact of Asymptomatic Superior Mesenteric Vein Thrombosis on the Outcomes of Patients with Liver Cirrhosis.	0
32	Living Donor Liver Transplantation for Budd-Chiari Syndrome: A Propensity Score-Matched Analysis. 2022 , 46, 2806-2816	O
31	Anti-hyperglycemic and antioxidant effect of fucoidan extract from Lessonia trabeculata in alloxan-induced diabetes rats.	0
30	Multidisciplinary approach for hepatocellular carcinoma arising from cirrhotic liver with Budd-Chiari syndrome: a case report. 2022 , 22, 202-206	O
29	Clinical outcomes of antithrombin îII-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.	0
28	The Role of Imaging in Portal Vein Thrombosis: From the Diagnosis to the Interventional Radiological Management. 2022 , 12, 2628	0
27	Efficacy and safety of thrombolytic therapy for portal venous system thrombosis: A systematic review and meta-analysis.	0
26	Budd¶hiari Syndrome Management: Controversies and Open Issues. 2022 , 12, 2670	O
25	Portal vein thrombosis in patients with COVID-19: A systematic review. 2022 ,	0
24	Enoxaparin attenuates Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression.	O

23	Non-Malignant Portal Vein Thrombosis in Liver Cirrhosis: Diagnosis and Treatment. 103-110	1
22	Hepatic Injury from Chemotherapy. 2022 , 409-416	О
21	Effects of bicyclol on hepatic sinusoidal obstruction syndrome induced by Gynura segetum. 2022 , 36,	0
20	Congestive Hepatopathy: A Case of Fontan-Associated Liver Disease and Review of Literature. 2022 , 27, 241-247	O
19	Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis. 12,	0
18	Vaskulle Lebererkrankungen. 2022 , 18, 329-346	О
17	Inferior Vena Cava Anomalies and Pathologies.	0
16	Incident portal vein thrombosis in liver transplant recipients in New Zealand: Predictors of risk and validation of portal vein thrombosis risk index calculator. 1,	O
15	Technical Feasibility of Suction Thrombectomy Using a Large-Bore Aspiration System in the PortoMesenteric Venous System. 2022 ,	0
14	Clinical anatomy of hepatic vessels by computed tomography angiography: A minireview. 15, 1-9	O
13	Clinical outcome comparison between transjugular intrahepatic portosystemic shunt and endoscopic treatment in patients with cavernous transformation of the portal vein presenting with variceal bleeding: A retrospective study.	О
12	Outcomes of Anticoagulation in Patients With Splanchnic Vein Thrombosis From Acute Pancreatitis. 2022 , 51, e105-e106	O
11	Development and external validation of prognostic scoring models for portal vein thrombosis: a multicenter retrospective study. 2023 , 21,	О
10	Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis. 2023 , 24, 2262	o
9	Non-Neoplastic Disorders of the Liver. 2024 , 489-556	0
8	Treatment of portal vein thrombosis in cirrhosis: a multicenter real life cahort study. 2023, 69,	O
7	Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature. 14, 99-116	О
6	Advance of New Oral Anticoagulants in the Treatment of Portal Vein Thrombosis in Cir-rhosis. 2023 , 13, 3788-3795	O

5	Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?. 2023 , 13, 1160	O
4	A 10-year Australian experience of rare intraabdominal venous thrombosis with comparison to deep vein thrombosis and pulmonary embolism. 2023 , 34, 191-198	O
3	Vascular Disorders. 2024 , 687-725	O
2	Early and Acute Complications and the Principles of HSCT Nursing Care. 2023 , 185-216	О
1	Interventional Treatment of Buddthiari Syndrome. 2023 , 13, 1458	0